%0 Generic %A H., Shibaguchi %A H., Tsuru %A M., Kuroki %D 2012 %T Supplementary Material for: Enhancement of the Antitumor Effect on Combination Therapy of an Anticancer Drug and Its Antibody against Carcinoembryonic Antigen %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Enhancement_of_the_Antitumor_Effect_on_Combination_Therapy_of_an_Anticancer_Drug_and_Its_Antibody_against_Carcinoembryonic_Antigen/5123356 %R 10.6084/m9.figshare.5123356.v1 %2 https://karger.figshare.com/ndownloader/files/8709082 %2 https://karger.figshare.com/ndownloader/files/8709085 %2 https://karger.figshare.com/ndownloader/files/8709088 %K Human anti-carcinoembryonic antigen antibodies %K Immunotherapy %K Anoikis %K Complement-dependent cytotoxicity %K Chemotherapy %K Antibody-dependent cell-mediated cytotoxicity %X Background: Carcinoembryonic antigen (CEA) is frequently overexpressed in various types of human cancers and is associated with cell adhesion. There are three possible mechanisms of cancer therapy that employ anti-CEA antibody (Ab): Ab-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) or the prevention of CEA interaction with the extracellular matrix and/or intercellular adhesion molecules resulting in anoikis. In this study, the effect of C2-74, a human anti-CEA monoclonal Ab was evaluated. Methods: ADCC, CDC and anoikis assays in combination with C2-74 and an anticancer drug (5-fluorouracil or cisplatin) were investigated using tumor cell lines (MKN-45, MKN-74 and KATO III). In the anoikis assay, other human anti-CEA Abs and mouse anti-CEA-related cell adhesion molecule 6 Abs were also investigated using HLC-1 cells. Results: Additive cytotoxicity was observed when the anticancer drug and C2-74 on tumor cells were combined in the CDC assays, whereas in the anoikis assay, no such additive effect was observed. Anti-CEA-related cell adhesion molecule 6 Abs, but not anti-CEA Abs, accelerated anoikis in HLC-1 cells. Conclusion: A mechanism for the additive antitumor effect when an anticancer drug and C2-74 are combined is indicated mainly by CDC activity but is irrelevant to anoikis in tumor cells. %I Karger Publishers